Tevogen Bio Holdings Inc. (TVGN) Q3 2025 10-Q Quarterly Report
Filed: Nov 14, 2025Period ending Sep 30, 2025
Health Care
Biological Products, (No Diagnostic Substances)SEC EDGAR Tevogen Bio Holdings Inc. (TVGN) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 14, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
Tevogen Bio Holdings Inc. Q3 2025 10-Q Analysis
Risk Factors
- • New risk: Nasdaq non-compliance due to Common Stock closing bid below $1.00 for 30+ days as of Sept 23, 2025
- • Material update: Nasdaq gives 180 days to regain $1.00 bid compliance, or risk delisting by March 23, 2026
- • Regulatory risk: Potential Nasdaq delisting could impair stock liquidity and market price significantly
- • Operational risk: High cash burn on TVGN 489 clinical, AI initiative, and other development programs requires substantial financing
- • Financial risk: Convertible Preferred Stock, Loan and Sales Agreements may cause significant shareholder dilution and restrict financing flexibility
Tevogen Bio Holdings Inc. Q3 2025 Quarterly FinancialsXBRL
Net Income
-$6M
▲ +2.7% YoY▼ -4.0% QoQ
ROE
73.2%
Total Assets
$4M
EPS (Diluted)
$-0.03
▼ -110.7% YoY▼ -50.0% QoQ
Operating Cash Flow
-$4M
▲ +4.1% YoY▼ -14.4% QoQ
Source: XBRL data from Tevogen Bio Holdings Inc. Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.
Get deeper insights on Tevogen Bio Holdings Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.